"The more technical explanation is not achieving a pre-specified boundary condition for stopping the trial early," Clive Meanwell, CEO of The Medicines Co. (MDCO), told BioWorld Today, referring to the recommendation of an independent data monitoring committee to continue the phase II MILANO-PILOT study of MDCO-216 following a planned interim analysis of the first 40 patients who completed treatment.